Acquisition and clearance of multidrug resistant Acinetobacter baumannii on healthy young adults concurrently burned in a dust explosion in Taiwan: the implication for antimicrobial stewardship

Table 2 Comparison of antimicrobial use among the eight^a MDRAB cases before and after the occurrence of MDRAB

	Before	After	P value
Time-at-risk, patient-days^b	130	98
All antibiotics, DOT (DOT/1000 patient-days)	1923 (1685–2161)	2286 (1986–2585)	0.113
Carbapenem	708 (563–852)	469 (334–605)	0.003
Non-carbapenem Beta-lactam	246 (161–331)	612 (457–767)	< 0.001
Glycopeptide	846 (688–1004)	939 (747–1131)	0.424
Miscellaneous	123 (63–183)	265 (163–367)	0.016
Antifungal agent	392 (285–500)	765 (592–939)	< 0.001

^aOne of the nine patients was excluded from the analysis. For this patient, only one MDRAB isolate was discovered from a removed central venous catheter (CVC) and there was no further MDRAB isolation from CVC available during study period. Thus, clearance of MDRAB was not defined and the analysis did not include the patient
^bTime-at-risk before MDRAB occurrence was the time from admission to MDRAB isolation. Time-at-risk after MDRAB occurrence was the time from MDRAB isolation to MDRAB clearance
Data are expressed as days of therapy (DOTs) and accumulated DOTs per 1000 patient-days
DOT days of therapy, MDRAB multidrug-resistant Acinetobacter baumannii

ISSN: 1471-2334